Evommune, Inc.: RA CAPITAL MANAGEMENT, L.P. amends Schedule 13D stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
RA Capital Management amended its Schedule 13D filing on Evommune, Inc., disclosing a change to its beneficial ownership stake in the company, per SEC accession 0001346824-26-000259. The filing signals the healthcare-focused investor's updated position in the clinical-stage immunology and inflammation drug developer. The exact size and direction of the stake change were not specified in the filing headline. Investors will watch for further detail in the amended 13D and any subsequent Form 4 filings to gauge RA Capital's conviction in Evommune's pipeline.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13D's report. It can get details wrong, so check the source.
Named in this story
Evommune, Inc., RA Capital Management, L.P.